We are happy to announce that AnalysisMode (Finland), Ceidos (Switzerland), IRUBIS (Germany), Nanolyze (Sweden) and Nyctea Technologies (Sweden) will be joining us at Testa Center in March 2023!
The countdown to the Testa Challenge weeks has officially begun and we look forward to welcome the selected companies to Testa Center.
Scroll down to learn more about the companies and their innovations!
// The Testa Challenge Team
AnalysisMode has developed an AI-powered bioprocessing simulator to better design, model, and execute bioprocesses. Their bioprocess simulator assists scientists to make data-based and more informed decisions therefore saving time, costs, and energy. AnalysisMode's mission is to model bioprocesses across different products and therapies to make treatments accessible to everyone. They believe that by using their solution, stakeholders can cut down costs drastically and gain insights not possible with already existing technologies.
Ceidos revolutionizes the way to monitor cell cultures in bioreactors with a fully automated in-line analyzer, the C-Netics. The C-Netics is an innovative laboratory device that fully automates cell expansion monitoring in real time, ensuring better outcomes at a much lower price.
IRUBIS specializes in mid-infrared (MIR) spectroscopy for bioprocessing. Their instrument, Monipa, is specifically designed for bioprocess monitoring and control. Monipa is based on MIR spectroscopy which makes it possible to monitor multiple bioprocesses online at the same time. Applications of the instrument are foreseen in both upstream bioprocessing; in metabolite monitoring and control, as well as in downstream bioprocessing to aid in aggregation studies, contaminant detection or monitoring of target proteins and excipients.
Nanolyze vision is to enable novel therapies by providing nanoscience with state-of-the-art technology in an easy-to-use wrapping. Nanoparticle analysis often require several processing steps and a single measurement can be time consuming. Therefore, they have our starting point in waveguide technology, and focus on simple setup, minimal preparation need, and intuitive analysis methods. Currently, they focus on applications for biological nanoparticles and we act in the overlapping field of physics and biology.
Nyctea delivers a new solution for non-invasive processing of biopharmaceuticals for improved productivity resulting in affordable medicine for patients. The company is based on an invention of a surface that purifies biomolecules by electronic signals that replace the use of problematic chemicals in the production process, giving faster production and higher yield. Their product enables manufacture of more kinds of biopharmaceuticals and accelerates the development of new treatments against diseases.